Products & ReviewLife Sciences
Everolimus
mTOR pathway inhibitor; Inhibits FKBP-12
Everolimus
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR). It is a hydroxyethyl ether-substituted derivative of rapamycin with improved pharmacokinetic and pharmacodynamic properties. It inhibits both mTORC1 and mTORC2 complexes by binding to FK506-binding protein (FKBP-12), which then binds to mTOR, leading to complex destabilization and blocked kinase function (Zeng et al.; Lebwohl et al.; Sedrani et al.; Huang & Houghton).
CANCER RESEARCH
- Inhibits cell proliferation, metabolism, and angiogenesis in a variety of cancers using in vitro and in vivo models (Zhu et al.; Lane et al.; O'Reilly et al.; Lebwohl et al.).
IMMUNOLOGY
- Acts as an immunosuppressive agent in the context of organ transplantation (Lebwohl et al.; Wullschleger et al.).
